GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen Marseille SA (STU:IPK) » Definitions » Minority Interest

Qiagen Marseille (STU:IPK) Minority Interest : €0.00 Mil (As of Dec. 2014)


View and export this data going back to . Start your Free Trial

What is Qiagen Marseille Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Qiagen Marseille's minority interest for the quarter that ended in Dec. 2014 was €0.00 Mil.


Qiagen Marseille Minority Interest Historical Data

The historical data trend for Qiagen Marseille's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen Marseille Minority Interest Chart

Qiagen Marseille Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Minority Interest
Get a 7-Day Free Trial - - - - -

Qiagen Marseille Semi-Annual Data
Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Qiagen Marseille Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Qiagen Marseille Business Description

Traded in Other Exchanges
N/A
Address
Qiagen Marseille SA develops molecular diagnostic tests designed to map diseases in order to guide patients and oncologists decisions along their complex therapeutic path.

Qiagen Marseille Headlines

No Headlines